The potential use of expression profiling: Implications for predicting treatment response in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 72, Issue 7, 2013, Pages 1118-1124

  Smith, Samantha Louise ^a   Plant, Darren ^b   Eyre, Stephen ^a   Barton, Anne ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AZATHIOPRINE; INFLIXIMAB; INTERFERON; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CLINICAL PRACTICE; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA MICROARRAY; DRUG COST; DRUG SAFETY; GENE EXPRESSION PROFILING; GENE LOCUS; GENE OVEREXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; RNA SEQUENCE; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TREATMENT RESPONSE;

INFECTIONS; RHEUMATOID ARTHRITIS; TREATMENT;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; GENE EXPRESSION PROFILING; HUMANS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84878404904     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202743     Document Type: Review

References (53)

1. Roses AD, St Jean PL, Ehm MG. Use of whole-genome association scans in disease gene identification, drug discovery and development. IDrugs 2007;10:797-804. (Pubitemid 350034526)
2. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6:287-93. (Pubitemid 46505879)
3. Wellcome Trust Sanger Institute. The Human Genome Project. 2011. http://www.sanger.ac.uk/about/history/hgp/ (accessed Aug 2012).
4. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79. (Pubitemid 351214284)
5. Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort Study. Clin Infect Dis 2006; 43:99-102. (Pubitemid 43939082)
6. Zucman D, Truchis P, Majerholc C, et al. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007;45:1-3. (Pubitemid 46684436)
7. Jabin D, Kumar S, Gow PJ. Outcome of patients on azathioprine: a need for a better pre-treatment assessment and dosing guideline. NZ Med J 2010;123:67-73.
8. US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labels. 2012. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ Pharmacogenetics/ucm083378.htm (accessed Aug 2012).
9. Reuther LO, Vainer B, Sonne J, et al. Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity. Eur J Clin Pharmacol 2004;59:797-801. (Pubitemid 38221656)
10. National Institute for Health and Clinical Excellence. TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor and TA198 Rheumatoid arthritis - tocilizumab: costing template. 2010. http://guidance. nice.org.uk/TA195/CostingTemplate/xls/English (accessed Jun 2012).
11. Prajapati R, Plant D, Barton A. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 2011;12:1571-85.
12. Plant D, Bowes J, Potter C, et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011;63:645-53.
13. Alvarado MD, Jensen EH, Yeatman TJ. The potential role of gene expression in the management of primary and metastatic colorectal cancer. Cancer Control 2006;13:27-31. (Pubitemid 43327551)
14. Dubois PC, Trynka G, Franke L, et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010;42:295-302.
15. Trynka G, Wijmenga C, van Heel DA. A genetic perspective on coeliac disease. Trends Mol Med 2010;16:537-50.
16. Dendrou CA, Plagnol V, Fung E, et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 2009;41:1011-15.
17. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009;10:57-63.
18. National Centre for Biotechnology Information. Microarrays: chipping away at the mysteries of science and medicine. 2007. http://www.ncbi.nlm.nih.gov/ About/primer/microarrays.html (accessed Jul 2012).
19. Katagiri F, Glazebrook J. Overview of mRNA expression profiling using DNA microarrays. Curr Protoc Mol Biol 2009;22:22.4.1-22.4.13.
20. Tan PK, Downey TJ, Spitznagel EL Jr, et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 2003;31:5676-84. (Pubitemid 37441938)
21. Nagalakshmi U, Wang Z, Waern K, et al. The transcriptional landscape of the yeast genome defined by RNA sequencing. Science 2008;320:1344-9. (Pubitemid 351929471)
22. Tillinghast GW. Microarrays in the clinic. Nat Biotechnol 2010;28:810-12.
23. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001;29:365-71. (Pubitemid 34326681)
24. Shi L, Reid LH, Jones WD, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006;24:1151-61. (Pubitemid 44359727)
25. Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 2010;11:733-9.
26. McGuire WL. Steroid receptors in human breast cancer. Cancer Res 1978;38:4289-91. (Pubitemid 9054219)
27. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81. (Pubitemid 29220854)
28. Houston SJ, Plunkett TA, Barnes DM, et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999;79:1220-6. (Pubitemid 29087902)
29. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99:167-70.
30. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol 2008;26:1059-65.
31. Carr M, May FE, Lennard TW, et al. Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription-polymerase chain reaction. Br J Cancer 1995;72:1427-34. (Pubitemid 26002653)
32. Davies N, Moir G, Carpenter R, et al. ERICA predicts response to tamoxifen in elderly women with breast cancer. Ann R Coll Surg Engl 1991;73:361-3.
33. Visvanathan K, Chlebowski RT, Hurley P, et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235-58.
34. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
35. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78. (Pubitemid 32230890)
36. Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 2003;9:5078-84. (Pubitemid 37413555)
37. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-38. (Pubitemid 24194147)
38. Raterman HG, Vosslamber S, de RS, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012;14:R95.
39. Meugnier E, Coury F, Tebib J, et al. Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-alpha treatments. Physiol Genomics 2011;43:365-71.
40. Lindberg J, Wijbrandts CA, van Baarsen LG, et al. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis. PLoS One 2010;5:e11310.
41. Julià A, Erra A, Palacio C, et al. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One 2009;4:e7556.
42. Julià A, Barceló M, Erra A, et al. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells. Pharmacogenomics 2009;10:1697-708.
43. van Baarsen LG, Wijbrandts CA, Rustenburg F, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010;12:R11.
44. Koczan D, Drynda S, Hecker M, et al. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 2008;10:R50.
45. Bansard C, Lequerré T, Derambure C, et al. Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra). Rheumatology (Oxford) 2011;50:283-92.
46. Stuhlmüller B, Häupl T, Hernandez MM, et al. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol Ther 2010;87:311-21.
47. Lequerré T, Gauthier-Jauneau AC, Bansard C, et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006; 8:R105.
48. Badot V, Galant C, Nzeusseu TA, et al. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res Ther 2009;11:R57.
49. Vosslamber S, Raterman HG, van der Pouw Kraan TC, et al. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis 2011;70:1153-9.
50. Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 2010;62:3607-14.
51. Fairfax BP, Makino S, Radhakrishnan J, et al. Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat Genet 2012;44:502-10.
52. Mallone R, Mannering SI, Brooks-Worrell BM, et al. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol 2011;163:33-49.
53. Scirè CA, Epis O, Codullo V, et al. Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure. Arthritis Res Ther 2007;9:R101.